Denosumab vs Alendronate Head-to-Head: 12-Month Postmenopausal BMD — Denosumab Wins Spine, Hip, and Forearm
The standard of postmenopausal osteoporosis drug selection is being re-examined. A comparative effectiveness analysis published in the Journal of Bone and Mineral Research compared denosumab (Prolia) 60mg subcutaneous every 6 months vs alendronate (Fosamax) 70mg weekly oral over 12 months. Denosumab was statistically superior in spine, hip, and forearm BMD. The 2026 guideline updates strengthen denosumab’s position as a first-line option.
Denosumab is a monoclonal antibody that blocks RANKL (receptor activator of nuclear factor kappa-B ligand). RANKL is a signal secreted by osteocytes that stimulates osteoclast formation and activity. Denosumab’s direct RANKL blockade suppresses osteoclast activity and reduces bone resorption. Bisphosphonates (alendronate, risedronate, zoledronate) also have antiresorptive effects but through different mechanisms (acting on osteoclasts to reduce activity and survival).
12-month comparative efficacy:
- Lumbar spine BMD: denosumab superior (~1~2% additional gain)
- Hip (femoral neck) BMD: denosumab superior
- Forearm BMD: denosumab superior (alendronate is weak at this site)
- Fracture rate: too low at 12 months for statistical significance — long-term follow-up needed
Clinical advantages of denosumab:
-
No GI burden: Alendronate requires demanding rules (morning fasting, 30 minutes upright, full glass of water) due to esophagitis and gastric irritation concerns. Denosumab injection bypasses all these.
-
6-month dosing: Weekly pill vs 6-month injection. Adherence difference is large. Alendronate 1-year adherence below 50%; denosumab over 80%.
-
Usable in renal impairment: Bisphosphonates restricted at eGFR < 35. Denosumab is independent of renal function.
-
Forearm efficacy: Bisphosphonates are weak at non-spine sites (forearm, distal femur) where denosumab outperforms.
Disadvantages and cautions:
-
Rebound fracture risk: Discontinuation of denosumab or delayed redosing (>7 months) causes RANKL signal to rebound dramatically, raising multi-vertebral fracture risk. If discontinuing, transition to an antiresorptive (alendronate, zoledronate) is mandatory.
-
Osteonecrosis of the jaw (ONJ) risk: Similar to bisphosphonates. Physician consultation needed before invasive dental procedures. Incidence rate is low (0.01~0.1%).
-
Atypical femoral fracture: Very rare with long-term use. Reassess at 5~7 years.
-
Hypocalcemia: Caution in renal impairment. Adequate calcium + vitamin D supplementation essential.
-
Cost: Denosumab 6-month dose runs about ₩600,000–800,000 out-of-pocket (post-Korean insurance). More expensive than alendronate at ₩10,000–20,000 monthly, but specialty disease cost reimbursement available for osteoporosis.
Patient selection guide for women:
- Elderly + high risk + GI burden: denosumab first-line
- Renal impairment: denosumab first-line
- Younger postmenopausal + low-to-moderate risk + cost-sensitive: alendronate first-line
- 5+ years on bisphosphonate with effect plateau: switch to denosumab or romosozumab
- Very high risk + fracture history: romosozumab 1 year → denosumab or alendronate transition (sequential)
Lifestyle matrix works alongside medication:
- Calcium 1,200mg/day (combined diet + supplementation)
- Vitamin D 2,000~4,000 IU/day (25(OH)D ≥ 30 ng/mL)
- Protein 1.0–1.2g/kg/day (substrate for bone synthesis)
- Resistance training 2~3×/week (osteocyte stimulation)
- Balance exercise (fall prevention)
- No smoking + alcohol restraint
Postmenopausal osteoporosis prevalence in Korean women is estimated at 30–50%, but diagnosis and treatment rates remain very low. DXA scanning is standard immediately post-menopause and every 2 years after. Drug initiation at T-score < -2.5; in patients with prior fracture history, drug consideration starts at T-score < -1.5. Denosumab is increasingly settling as a first-line option in Korean clinical practice.